Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)

Authors
Category Primary study
JournalBLOOD
Year 2021
This article has no abstract
Epistemonikos ID: 6957cf25928470c8f2e2d862900fb0a8cccd48be
First added on: Feb 13, 2025